Recursion Pharmaceuticals Q4 2023 GAAP EPS $(0.42) Beats $(0.44) Estimate, Sales $10.89M Miss $20.35M Estimate
Recursion Pharmaceuticals Q4 2023 GAAP EPS $(0.42) Beats $(0.44) Estimate, Sales $10.89M Miss $20.35M Estimate
Recursion Pharmaceuticals 2023年第四季度GAAP每股收益美元（0.42美元）超過預期（0.44美元），銷售額爲1,089萬美元，低於2,035萬美元的預期
Recursion Pharmaceuticals (NASDAQ:RXRX) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.44) by 4.55 percent. This is a 35.48 percent decrease over losses of $(0.31) per share from the same period last year. The company reported quarterly sales of $10.89 million which missed the analyst consensus estimate of $20.35 million by 46.49 percent. This is a 20.36 percent decrease over sales of $13.68 million the same period last year.
Recursion Pharmicals（納斯達克股票代碼：RXRX）公佈的季度虧損爲每股0.42美元，比分析師普遍預期的0.44美元（0.44美元）高出4.55％。與去年同期每股虧損0.31美元（0.31）相比，下降了35.48％。該公司公佈的季度銷售額爲1,089萬美元，比分析師普遍預期的2,035萬美元低46.49％。這比去年同期的1,368萬美元的銷售額下降了20.36％。